Immune Response mit Quartalszahlen...
Drogo : Immune Response mit Quartalszahlen...
Durchschnittserwartung der Analysten: -8 cents/share oder -31 cents für 2000
Geliefert: +1 cent/share....!!!
Cash steigt von 23 Mio.$ auf 29 Mio.
Bitte Nasdaq, laß das nicht einfach so vorrübergehen, auch wenns ein Biotech Research Laden ist und eigentlich schnuppe.
The Immune Response Corporation Announces First Quarter 2000 Financial Results
CARLSBAD, Calif., May 11 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) today announced its financial results for the quarter ended
March 31, 2000. The net income for the first quarter of 2000 was $421,000, or
$.01 per share, compared to a net loss of $1.3 million, or a loss of $.07 per
share, reported in the first quarter of 1999.
Research related revenue for the quarter ended March 31, 2000 was
$3.3 million compared to $9.2 million for the same quarter in 1999. The
decrease in research related revenue was primarily attributable to a
$5.0 million milestone payment from Agouron Pharmaceuticals, Inc. ("Agouron"),
a Warner-Lambert Company, paid in the first quarter of 1999. In addition to
research related revenue, the Company received non-research revenue from
investment and other income of $3.3 million for the first quarter of 2000
versus $380,000 for the same period in 1999. This other revenue was primarily
due to the sale of an equity security held for sale that was acquired through
the licensing of technology and from the sale of undeveloped property.
Operating expenses decreased to $6.2 million for the quarter ended March
31, 2000 from $10.9 million in the first quarter of 1999. The decrease in
operating expenses was primarily the result of the Company's workforce
reduction in June 1999, along with a decrease in clinical and regulatory
Cash, cash equivalents and short-term investments were $29.2 million at
March 31, 2000 compared with $23.1 million at the end of 1999.
ein hoffender Drogo
Mr.Fresh : Mit Gewinn hab ich nicht gerechnet!!!
Kicky : und hier die Nachricht von gestern-der Gewinn ist ja wirklich sehr positiv
The Immune Response Corporation (Nasdaq: IMNR) and Agouron Pharmaceuticals, Inc.
today announced that a pivotal trial has been initiated to evaluate the safety
and efficacy of the investigational product REMUNE(TM) (HIV-1 Immunogen) in
increasing durability of viral suppression for people infected with HIV, when
added onto their current antiretroviral regimens. This trial will be conducted
through the Adult AIDS Clinical Trial Group (AACTG). REMUNE is the first
investigational therapeutic vaccine to be tested by the AACTG in a pivotal
The AACTG is a multicenter cooperative clinical trials group funded by the
Division of AIDS, National Institute of Allergy and Infectious Diseases of the
National Institutes of Health. It is involved in various phases of clinical
research, from early safety studies to large-scale efficacy trials. It evaluates
new drugs and drug combinations for the treatment of HIV infection in adults.
"Previous clinical studies have suggested that when combination antiviral drug
therapy is accompanied by intramuscular injections of REMUNE administered once
every three months, improvements in markers of the immune response to HIV and
positive trends in virologic markers are observed," said Fred Valentine, M.D.,
of Bellevue Hospital, New York University Medical Center, and Protocol Chair of
the newly initiated trial. "Based on such data, we have chosen to test REMUNE in
the AACTG clinical development program."
In clinical trials conducted to date with REMUNE, with or without antiviral drug
therapy, the most frequently reported side effects include local transient pain,
soreness and redness at the site of injection, muscle aches, fatigue, and
The primary objective of this 96 week, randomized, double-blind,
adjuvant-controlled study is to determine whether the addition of REMUNE to a
regimen of potent, suppressive antiretroviral therapy delays the time to
virologic relapse (defined as a predetermined level of HIV-1 RNA detected in the
plasma). The trial is expected to enroll a total of 472 people and will be open
to all Adult AIDS Clinical Trial Units and their subunits. The first scheduled
data analysis of the trial will be conducted at 48 weeks to assess differences
between control and REMUNE-treated groups in time to virological relapse.
werde mir sie jetzt irgendwann wieder holen
Mr.Fresh : D.h. zu Deutsch
werden nun die klinischen Tests auch in den USA gestartet.
Remune ist das erste Präparat gegen Aids, das in diese Testphase gelangt!!!
Drogo : Haha..jetzt gehts lohos, jetz gehts lohos...noch eine Meldung von heute, gerade eben:
NIH to test Remune AIDS virus vaccine
NEW YORK, May 11 (Reuters) - The U.S. National Institutes
of Health will begin a pivitol trial of the experimental Remune
vaccine for people infected with the AIDS virus, said Immune
Response Corp. , the vaccine's maker.
In a statement on Wednesday, Immune Response said that in
the tests Remune will be added to standard combination drug
therapy for patients infected with the AIDS virus, HIV.
Remune is a so-called therapeutic vaccine and is intended
to stimulate the immune system to destroy HIV-infected cells.
The study is aimed at determining whether Remune, when used in
combination with standard therapies, can suppress levels of HIV
in the blood longer than standard therapy taken alone.
Carlsbad, Calif-based Immune Response said the trial is
expected to enroll 472 people. The first scheduled data
analysis of the trail will be conducted at 48 weeks to assess
differences betwen control and Remune-treated groups.
((New York Newsroom 212-859-1700))